<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594707</url>
  </required_header>
  <id_info>
    <org_study_id>WA42294</org_study_id>
    <secondary_id>2020-001429-30</secondary_id>
    <nct_id>NCT04594707</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of&#xD;
      recombinant human pentraxin-2 (rhPTX-2; PRM-151) administered by intravenous (IV) infusion to&#xD;
      participants with idiopathic pulmonary fibrosis (IPF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted for the treatment of eligible participants who have taken part&#xD;
      in Study PRM-151-202 and received the open-label study drug or completed the Phase III Study&#xD;
      WA42293 with PRM-151. Participants who have discontinued treatment from or have completed&#xD;
      Study WA42293 and do not want to receive PRM-151 in this study, will be invited to enroll in&#xD;
      survival follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">July 11, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AE)</measure>
    <time_frame>From baseline until 8 weeks after the final dose</time_frame>
    <description>Severity will be determined according to the 5-point severity scale (National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 [NCI CTCAE, v.5.0]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Infusion Related Reactions (IRRs) and other AEs of Special Interest</measure>
    <time_frame>From baseline until 8 weeks after the final dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of of Participants Permanently Discontinuing Study Treatment due to AEs</measure>
    <time_frame>From baseline until 8 weeks after the final dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Targeted Clinical Laboratory Test Results</measure>
    <time_frame>From baseline until 8 weeks after the final dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Decline in Forced Vital Capacity (FVC) (mL)</measure>
    <time_frame>From baseline until study completion (up tp 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in 6-Minute Walk Distance (6MWD)</measure>
    <time_frame>From baseline until study completion (up tp 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Decline in FVC% Predicted</measure>
    <time_frame>From baseline until study completion (up tp 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Time to first occurrence of a significant FVC decline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ)</measure>
    <time_frame>Day 1, Week 24 and then every 24 Weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in St. George Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>Day 1, Week 24 and then every 24 Weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Carbon Monoxide Diffusing Capacity (DLCO)</measure>
    <time_frame>Day 1, Week 24 and then every 24 Weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Every 6 Months and at study completion (up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of PRM-151 at Specified Timepoints</measure>
    <time_frame>Days 1, 3 and 5, Weeks 4, 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Anti-drug Antibodies (ADAs) to PRM-151 at Baseline</measure>
    <time_frame>Baseline (Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ADAs During the Study</measure>
    <time_frame>Weeks 4, 12 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>PRM-151</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corhort A: Participants entering, following participation in study PRM-151-202.&#xD;
Cohort B: Participants entering, following participation in study WA42293.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRM-151</intervention_name>
    <description>Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.&#xD;
Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo.</description>
    <arm_group_label>PRM-151</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Taken part in either of the prior PRM-151 studies: PRM-151-202 or WA42293.&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraception.&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             a condom, and agreement to refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute respiratory or systemic bacterial, viral, or fungal infection at the first visit&#xD;
             of the OLE, or within 2 weeks of the first visit for patients joining Cohort A (from&#xD;
             Study PRM-151-202).&#xD;
&#xD;
          -  History of smoking within 3 months prior to the first visit in the OLE.&#xD;
&#xD;
          -  History of alcohol or substance use disorder within 2 years prior to the first visit&#xD;
             of the OLE or known or suspected active alcohol or substance-use disorder.&#xD;
&#xD;
          -  History of severe allergic reaction or anaphylactic reaction to PRM-151.&#xD;
&#xD;
          -  Clinically significant abnormality on ECG during eligibility assessment including&#xD;
             prolonged corrected QT interval &gt; 450 ms (for men) or &gt; 470 ms (for women) based on&#xD;
             the Fridericia correction formula; or laboratory tests (hematology, serumchemistry,&#xD;
             and urinalysis) that, in the opinion of the investigator, may pose an additional risk&#xD;
             in administering study drug to the participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WA42294 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bassetti Medical Research, Inc</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33870-1216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jefferson University Physicians (JUP) - Jefferson Pulmonary</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Lung Clinic, PA</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Univ. Senese Policlinico S. Maria alle Scotte; Dip. Medicina clinica e Scienze Immunologiche</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

